Your session is about to expire
← Back to Search
Participants without Parkinson disease for Psychogenic Movement Disorders (mPower Trial)
N/A
Waitlist Available
Led By Lara Mangravite, PhD
Research Sponsored by Sage Bionetworks
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights
No Placebo-Only Group
Summary
The purpose of this study is to understand variation in the symptoms of Parkinson disease. This study uses an iPhone app to record these symptoms through questionnaires and sensors.
Eligible Conditions
- Psychogenic Movement Disorders
- Parkinson's Syndromes
- Multiple System Atrophy
- Extrapyramidal Disorder
- Neurodegenerative Disease
- Limbic-predominant Age-related TDP-43 Encephalopathy
- Dementia
- Central Nervous System Disease
- Brain Diseases
- Central Nervous System Disorders
- Parkinson's Disease
- Movement Disorders
- Basal Ganglia Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
App usage data for assessment of participant engagement
Digital audio signals of sustained phonation from phonation intervention
Gyroscope and accelerometer sensor measurements from gait and balance intervention
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Participants without Parkinson diseaseExperimental Treatment7 Interventions
People who do not report a diagnosis of Parkinson disease. Participants are invited via the Parkinson mPower mobile application to complete the following behavioral interventions: Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, and Participant open-response writing.
Group II: Participants with Parkinson diseaseExperimental Treatment7 Interventions
People who report a diagnosis of Parkinson disease. Participants are invited via the Parkinson mPower mobile application to complete the following behavioral interventions: Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, and Participant open-response writing.
Find a Location
Who is running the clinical trial?
Sage BionetworksLead Sponsor
4 Previous Clinical Trials
9,094 Total Patients Enrolled
Robert Wood Johnson FoundationOTHER
158 Previous Clinical Trials
675,900 Total Patients Enrolled
Lara Mangravite, PhDPrincipal InvestigatorSage Bionetworks
Share this study with friends
Copy Link
Messenger